REpeat Intervention For Failed Surgical BioProsthEtic AorTic Valves (REPEAT)

The overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for heart failure or aortic valve re-intervention at 5 years.

NCT Number	NCT07462624
Lead Sponsor	Heart Center Leipzig - University Hospital Collaborators: University of Leipzig, Helios Health Institute GmbH
Conditions	Degenerative Aortic Valve Disease
Enrollment	890 participants
Start Date	2025-11-10
Primary Completion	2033-09-30 (estimated)
Study Completion	2033-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-10